Delcath Systems (NASDAQ:DCTH) Trading 1.6% Higher

Delcath Systems, Inc. (NASDAQ:DCTH) shares traded up 1.6% on Tuesday . The company traded as high as $5.72 and last traded at $5.60. 220,934 shares were traded during trading, a decline of 2% from the average session volume of 225,808 shares. The stock had previously closed at $5.51.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the stock. StockNews.com upgraded shares of Delcath Systems to a “sell” rating in a research report on Wednesday, March 27th. HC Wainwright lifted their price target on shares of Delcath Systems from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, March 27th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Delcath Systems currently has an average rating of “Moderate Buy” and an average target price of $18.50.

Delcath Systems Stock Up 1.6 %

The firm has a market capitalization of $142.46 million, a price-to-earnings ratio of -1.89 and a beta of 0.53. The business’s 50-day simple moving average is $4.51 and its two-hundred day simple moving average is $3.94.

Delcath Systems (NASDAQ:DCTH) last announced its quarterly earnings data on Tuesday, March 26th. The company reported ($0.48) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.19. The firm had revenue of $0.54 million during the quarter, compared to analysts’ expectations of $0.48 million. Delcath Systems had a negative net margin of 2,308.86% and a negative return on equity of 563.60%. During the same quarter in the previous year, the business posted ($0.86) earnings per share. Sell-side analysts anticipate that Delcath Systems, Inc. will post -1.45 earnings per share for the current year.

Insider Activity at Delcath Systems

In other Delcath Systems news, Director Gil Aharon acquired 26,882 shares of the company’s stock in a transaction that occurred on Tuesday, March 19th. The stock was purchased at an average price of $3.72 per share, for a total transaction of $100,001.04. Following the completion of the acquisition, the director now owns 1,069,710 shares of the company’s stock, valued at approximately $3,979,321.20. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 17.94% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Vivo Capital LLC lifted its stake in Delcath Systems by 57.4% in the third quarter. Vivo Capital LLC now owns 1,855,191 shares of the company’s stock worth $7,514,000 after acquiring an additional 676,404 shares during the last quarter. AIGH Capital Management LLC purchased a new stake in shares of Delcath Systems during the 4th quarter worth approximately $4,918,000. Stonepine Capital Management LLC lifted its position in shares of Delcath Systems by 81.2% during the 3rd quarter. Stonepine Capital Management LLC now owns 686,240 shares of the company’s stock worth $2,779,000 after buying an additional 307,453 shares during the last quarter. Worth Venture Partners LLC purchased a new stake in shares of Delcath Systems during the 4th quarter worth approximately $1,224,000. Finally, ADAR1 Capital Management LLC purchased a new stake in shares of Delcath Systems during the 4th quarter worth approximately $962,000. Hedge funds and other institutional investors own 61.12% of the company’s stock.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.